Predicting treatment response in advanced prostate cancer
Part of Cancer clinical trials.
This study looks at how well a type of imaging scan called SPECT can predict treatment response in people who have already received at least two cycles of the therapy 177Lu-PSMA for advanced prostate cancer. It may help doctors understand how well the treatment is working and when to expect results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread and no longer responds to hormone therapy.
- You have already had at least two cycles of the treatment 177Lu-PSMA.
- You agree to let your medical data be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a special scan (dosimetry) can help predict how well PSMA radioligand therapy works for men with advanced prostate cancer that has spread. The therapy uses a radioactive drug to target and kill cancer cells that have a protein called PSMA.
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
This trial is testing whether a special PET scan before treatment can predict what dose of a radioactive drug will go to your cancer, helping doctors plan and personalize your care. The drug used is called 177Lu-PSMA-617, which targets prostate cancer cells that have a specific marker (PSMA).
Hear when a new Therapy-Associated Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.